Veradermics, Inc (MANE) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $989.26M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-895.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $543.04M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-524.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $2.35M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $60.00K.
- 2025-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m).
Veradermics, Inc Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $1.00K | $989.26M | $-895.00K | $-174.16M | $813.61M | 3 month · $3.52M |
| 2026-03-31 | $0.00 | $1.00K | $543.04M | $-524.00K | $-150.65M | $390.64M | 3 month · $5.26M |
| 2025-12-31 | $0.00 | $1.00K | $2.35M | $60.00K | $-123.42M | $-121.01M | 12 month · $1.44M |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | $-76.07M | 3 month · $115.00K |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | $-60.67M | 3 month · $213.00K |
| 2024-12-31 | (m) | $1.00K | $750.00K | $0.00 | $-49.23M | $-48.48M | 12 month · $250.00K |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | $-22.24M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |